Empagliflozin and Ezetimibe/Rosuvastatin in Healthy Volunteers
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 56 (estimated)
- Sponsor
- Hyundai Pharm · Industry
This trial is looking for healthy adults aged 19 and over to understand how two medications work together and ensure they are safe. Participants will take a specific dose of the medications for the study.
You may be able to join if
- I am 19 years old or older
- I have a body mass index (BMI) between 18.5 and 29.9
- I am a healthy volunteer
- I can provide signed consent
You may not be able to join if
- I have pre-existing diseases that could affect how study drugs work
- I have clinically relevant findings that could affect the study
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
Loading trial locations…